Old drug, new hope: niclosamide tested for tough childhood leukemia

NCT ID NCT05188170

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This early-phase trial tests niclosamide, a drug previously used for tapeworm infections, combined with standard chemotherapy in 16 children whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find a safe dose and check for side effects. Researchers will also look for signs that the treatment is shrinking the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niclosamide
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat AML.
What could go wrong: This is a very early Phase 1 trial with only 16 participants, so it may not lead to a proven therapy. There are also risks of serious side effects from the drug combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

Stanford University
RECRUITING

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.